



SmartPA Criteria Proposal

Drug/Drug Class:	Acne and Rosacea – Select Topical Agents Step Therapy Edit
First Implementation Date:	August 17, 2020
Revised Date:	July 27, 2023
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of select topical agents for acne and rosacea.

Why Issue Selected: Acne is a chronic inflammatory condition presenting as comedones, papules, pustules, and nodules. Oil production, dead skin cells, clogged pores, and bacteria can all work together to cause acne. Acne affects about 50 million people in the United States, including 85% of adolescents and 12% of adult women. There are a variety of agents for the treatment of acne with a wide range of cost.

Rosacea is a chronic inflammatory condition, predominately affecting the facial skin and eyes, which typically presents any time after 30 years of age as flushing or redness on the cheeks, nose, chin, or forehead that may come and go. Rosacea is estimated to affect over 16 million people in the United States. There are a variety of topical and oral agents available for the treatment of rosacea.

Due to the large patient population affected and the variety of therapies available, it is fiscally advantageous for MO HealthNet to manage utilization of higher cost therapies. This edit will focus on expensive topical agents that are not currently being edited by other means.

Program-Specific Information:

Date Range FFS 1-1-2022 to 12-31-2022				
	Drug	Claims	Spend	Avg Spend per Claim
AZELAIC ACID 15% GEL	227	\$13,310.17	\$58.64	
CLINDAMYCIN PHOS 1% FOAM	7	\$81.40	\$11.63	
CLINDAMYCIN PHOS 1% GEL	3	\$866.00	\$288.67	
DAPSONE 5% GEL	66	\$11,286.29	\$171.00	
DAPSONE 7.5% GEL PUMP	14	\$6,028.63	\$430.62	
FIANCEA 15% FOAM	7	\$2,203.60	\$314.80	
IVERMECTIN 1% CREAM	40	\$9,225.39	\$230.63	
METRONIDAZOLE 0.75% CRM	837	\$39,252.95	\$46.90	
METRONIDAZOLE 0.75% GEL	494	\$17,721.56	\$35.87	
METRONIDAZOLE 0.75% LOT	6	\$644.34	\$107.39	
METRONIDAZOLE 1% GEL	496	\$38,931.72	\$78.49	
METRONIDAZOLE 1% GEL PUMP	35	\$2,161.40	\$61.75	
MIRVASO 0.33% GEL PUMP	30	\$15,727.87	\$524.26	

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries. Other company trademarks are also acknowledged.

NORITATE 1% CREAM	3	\$5,906.97	\$1,968.99
RHOFADE 1% CREAM	23	\$12,390.64	\$538.72
SOD SURFACE-SULFUR 9-4.5% WASH	2	\$156.42	\$78.21
SOD SURFACE-SULF 9.8-4.8% CLSR	2	\$412.15	\$206.08

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Step Therapy Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Select topical agents for acne and rosacea
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- For treatment of acne vulgaris (Aczone and Azelex agents):
 - Documented diagnosis of acne vulgaris in the past 2 years **AND**
 - Documented therapeutic trial of topical benzoyl peroxide and topical clindamycin or erythromycin (defined as 30 out of 90 days)
 - Clinical consultant review required for agents flagged as high cost therapies (see Appendix A)
- For treatment of rosacea (Finacea, Metrocream, Metrogel, Metrolotion, Mirvaso, Noritate, Rhofade, Rosadan, and Soolantra agents):
 - Claim is for topical azelaic acid 15% gel, metronidazole 1% gel, or metronidazole 0.75% cream or gel **OR**
 - Documented diagnosis of rosacea in the past 2 years **AND**
 - Documented therapeutic trial of azelaic acid 15% gel, metronidazole 1% gel, or metronidazole 0.75% cream or gel (defined as 30 out of 90 days)
 - Clinical consultant review required for agents flagged as high cost therapies (see Appendix A)

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

X

Disposition of Edit

Denial: Exception code "0681" (Step Therapy Edit)
 Rule Type: CE

Default Approval Period

1 year

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
 Other company trademarks are also acknowledged.

Appendix A – High Cost Agents for Acne or Rosacea Therapy

Drug Description	Generic Equivalent
EPSOLAY 5% CREAM PUMP	BENZOYL PEROXIDE
BPO 6% FOAMING CLOTHS	BENZOYL PEROXIDE
CLINDACIN PAC KIT	CLINDAMYCIN PHOS/SKIN CLNSR 19 1% KIT
CLINDAGEL 1% GEL	CLINDAMYCIN PHOSPHATE
EVOCLIN 1% FOAM	CLINDAMYCIN PHOSPHATE
INOVA 4% EASY PAD	BENZOYL PEROXIDE/VITAMIN E MIXED
INOVA 8% EASY PAD	BENZOYL PEROXIDE/VITAMIN E MIXED
ROSADAN 0.75% CREAM KIT	METRONIDAZOLE/SKIN CLEANSR #23
ROSADAN 0.75% GEL KIT	METRONIDAZOLE/SKIN CLEANSR #23
ROSULA 10%-5% CLOTHS	SULFACETAMIDE SODIUM/SULFUR 10-5%
SOD SULFACETAMIDE-SULFUR LOT	SULFACETAMIDE SOD/SULFUR 10-5%(W/W)
SUMAXIN CLEANSING PADS	SULFACETAMIDE SODIUM/SULFUR 10%-4%
INOVA 4-1 EASY PAD	SALICYLIC ACID/BENZOYL PEROXIDE/ VITAMIN
SUMADAN 9%-4.5% WASH	SULFACETAMIDE SODIUM/SULFUR 9 %-4.5 %
PLEXION 9.8-4.8% CLEANSER	SULFACETAMIDE SODIUM/SULFUR 9.8%-4.8%
INOVA 8-2 EASY PAD	SALICYLIC ACID/BENZOYL PEROXIDE/ VITAMIN
BP 10-1 WASH	SULFACETAMIDE SODIUM/SULFUR 10%-1%
SSS 10-5 FOAM	SULFACETAMIDE SODIUM/SULFUR 10%-5%

References

- IPD Analytics. Dermatology: Acne. Accessed January 19, 2023.
- IPD Analytics. Dermatology: Rosacea. Accessed January 19, 2023.
- Maier, Lisa E. (2021). Management of rosacea. UpToDate. Accessed January 19, 2023.
- Graber, Emmy. (2021). Acne vulgaris: Overview of management. UpToDate. Accessed January 19, 2023.
- Zaenglein, A, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74: 945-73. <http://dx.doi.org/10.1016/j.jaad.2015.12.037>
- National Institute for health and Care Excellence (NICE). Acne vulgaris: management. [Acne vulgaris: management \(nice.org.uk\)](https://www.nice.org.uk/guidelines/ng17). June 2021. Accessed February 3, 2022.
- Schaller, M, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. British Journal of Dermatology. August 7, 2019. <https://doi.org/10.1111/bjd.18420>
- Hampton, P J, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021;185(4):725-735. doi:10.1111/bjd.20485. [British Association of Dermatologists guidelines for the management of people with rosacea 2021* - Hampton - 2021 - British Journal of Dermatology - Wiley Online Library](https://doi.org/10.1111/bjd.20485)
- Thiboutot, D, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2020; 82:1501-10. <https://doi.org/10.1016/j.jaad.2020.01.077>